Compared to clinical measures and neuropsychological testing, MRI-derived biomarkers require an order of magnitude smaller cohort size to detect disease-related changes over time.
such biomarkers will be equally effective in detecting the effects of disease-modifying treatments, and will allow smaller and shorter clinical trials.